Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$159.69 USD
+0.16 (0.10%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $159.69 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$159.69 USD
+0.16 (0.10%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $159.69 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth F Momentum D VGM
Zacks News
The Zacks Analyst Blog Highlights: Johnson & Johnson, Schlumberger, PayPal, Adobe and Philips
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Schlumberger, PayPal, Adobe and Philips
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic and Smith & Nephew
by Zacks Equity Research
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic and Smith & Nephew
Biogen (BIIB) Tops Q3 Earnings & Sales, Spinraza Sales Up
by Zacks Equity Research
Biogen (BIIB) exceeds both earnings and sales estimates in the third quarter of 2017. The company's newest drug Spinraza's continual strong performance drives its revenue.
Drug/Biotech Stocks Q3 Earnings on Oct 25: AMGN, GSK, VRTX
by Zacks Equity Research
The pharma/biotech industry has seen a solid start to Q3 earnings as evident from J&J's encouraging results. Let's see if some of the other leading players - Amgen, Glaxo and Vertex - follow suit.
Centene (CNC) Tops Q3 Earnings & Revenues, Raises '17 View
by Zacks Equity Research
Centene's (CNC) strong third-quarter earnings were driven by solid revenue growth.
Earnings Picture Further Improves
by Sheraz Mian
It's not news that corporate earnings are good, but this earnings season is spotlighting two incrementally new positives to the earnings backdrop.
Healthcare ETF (VHT) Hits New 52-Week High
by Zacks Equity Research
Healthcare ETF hits a new 52-week high amid strong earnings and talks of bipartisan deal.
Dow 30 Stock Roundup: AmEx, IBM, JNJ, Goldman Beat
by Swarup Gupta
The Dow experienced substantial gains over this week, powered primarily by strong earnings expectations and bullish results.
Healthcare ETFs Head to Head: XLV vs. VHT
by Zacks Equity Research
Head to head comparison of two Healthcare ETFs, XLV and VHT.
Healthcare ETFs in Focus on Johnson & Johnson Q3 Earnings
by Zacks Equity Research
Johnson & Johnson reports Q3 results with both revenues and EPS beating estimates.
Can ImmunoGen's Key Pipeline Cancer Candidate Drive Growth?
by Zacks Equity Research
Though ImmunoGen (IMGN) is progressing with lead ovarian cancer candidate, mirvetuximab soravtansine, the company is likely to face stiff market competition from established products upon approval.
Varian Medical (VAR) Initiates Halcyon Treatment in Europe
by Zacks Equity Research
Varian (VAR) has been taking initiatives to gain customers for its broad spectrum of products, especially targeting emerging markets.
Dow ETFs Soar as the Index Hits 23,000
by Sanghamitra Saha
Dow Jones Industrial Average hits 23,000 and benefits these ETFs.
Stock Market News For Oct 18, 2017
by Zacks Equity Research
Benchmarks finished higher on Tuesday after a slew of strong corporate earnings led gains for healthcare stocks.
J&J (JNJ) Beats on Q3 Earnings, Actelion Buyout Drives Sales
by Zacks Equity Research
J&J (JNJ) reported better-than-expected third-quarter 2017 results and raised its 2017 sales and profit outlook.
Market: Spectacular All Around
by Zacks Equity Research
Market: Spectacular All Around
Q3 Earnings Blasting Off: GS, MS, JNJ and More
by Mark Vickery
Stronger-than-expected earnings are providing a good tonic for us this morning, even as pre-markets are mixed at this hour.
J&J (JNJ) Beats on Q3 Earnings & Sales, Ups 2017 View
by Zacks Equity Research
Johnson & Johnson (JNJ) beat consensus estimate for both earnings and sales and also raised its 2017 sales and profit outlook.
5 Earnings All Stars to Start Off the Week
by Tracey Ryniec
Nervous about earnings season? This week, it pays to check in with these bellwether stocks.
J&J's Psoriasis Drug Stelara Gets FDA Nod for Adolescent Use
by Zacks Equity Research
Johnson & Johnson (JNJ) announced approval of label expansion for its plaque psoriasis drug, Stelara, to include adolescent patients.
MedTech Players Eyeing Emerging Market Growth Opportunities
by Zacks Equity Research
The gloomy eco-political scenario in the United States and Europe points toward the fact that emerging geographies are playing a crucial role in the growth of the MedTech space globally.
J&J (JNJ) to Kickstart Pharma Q3 Earnings: What's in Store?
by Zacks Equity Research
J&J's (JNJ) sales and earnings growth are expected to accelerate in third and fourth quarters. The company expects organic sales growth of 4% in the second half of the year.
Pfizer Considering Sale/Spin-Off of Consumer Healthcare Unit
by Zacks Equity Research
Pfizer (PFE) is exploring strategic alternatives for its Consumer Healthcare segment including a partial or a full separation through a spin-off, sale or other transaction.
Will Dow ETFs Continue to Shine in Q3 Earnings?
by Sweta Killa
The Dow Jones has returned 24.2% since the Election Day compared to a gain of 18.9% for the S&P 500.
Here's What's Has Happened in the HCV Space Lately
by Zacks Equity Research
A lot has happened in the hepatitis C virus space of late. The market is getting crowded and seeing increased pricing pressure.